Friday, 13 November 2026 IPO data updated 7 minutes ago
Live GMP Listing Today IPO Calendar IPO Alerts About Disclaimer
IPO Darbaar Every IPO · One Court
SP Symbiotec Pharmalab logo

Symbiotec Pharmalab IPO Listing Price, Gain & Allotment

Listed Mainboard IPO BSE, NSE
Listed 1 Sep 2026 · updated 2 months ago
Price band
₹988
GMP
+₹185
Est. listing price₹1,173
Est. listing gain18.72%
Issue size₹1,757 Cr
GMP Calculator Compare

Symbiotec Pharmalab IPO Details

Open DateMon, 24 Aug 2026
Close DateThu, 27 Aug 2026
Listing DateTue, 1 Sep 2026
Listing AtBSE, NSE
Price Band₹988 per share
Lot Size15 shares
Min. Investment₹14,820
Issue Size₹1,757 Cr

Symbiotec Pharmalab IPO Dates & Timeline

Tentative dates follow SEBI's T+3 listing timeline
IPO Opens
Mon, 24 Aug
IPO Closes
Thu, 27 Aug
Basis of Allotment
Fri, 28 Aug
Tentative
Refunds Initiated
Mon, 31 Aug
Tentative
Shares Credited to Demat
Mon, 31 Aug
Tentative
Listing Date
Tue, 1 Sep

Symbiotec Pharmalab IPO GMP Today

All IPO GMP
GMP today +₹185
Est. listing price ₹1,173
Est. gain % 18.72%
Est. profit / lot ₹2,775
GMP is an unofficial grey-market indicator and can change quickly. It does not guarantee listing gains. Try the GMP calculator · What is GMP? · GMP of all IPOs

Final visitor sentiment

Visitor opinion poll, not investment advice.
0 votes
Will apply 0%
Will skip 0%
Not sure 0%

Symbiotec Pharmalab IPO Subscription Status

As of 27 Aug, 7:00 PM
Retail (RII)
12.96x
NII / HNI
73.63x
bHNI (>₹10L)
82.92x
sHNI (₹2–10L)
55.07x
QIB
172.03x
Employees
15.41x
Total
71.26x

Times subscribed per category, from NSE (bids on NSE and BSE combined). Final figures after bidding closed.

Symbiotec Pharmalab IPO Listing Price & Gain

Issue price₹988
Listing price (NSE)₹988
Listing gain0.00%
Listing-day close₹1,097.7 (+11.1%)

The last GMP before listing (₹185) pointed to about ₹1,173; the shares opened 18.7 points below that estimate. How accurate is GMP?

Symbiotec Pharmalab IPO Allotment Status

The registrar for this IPO is MUFG Intime (Link Intime). You can also check on the exchange websites using your PAN or application number.

MUFG Intime (Link Intime) BSE NSE

New to this? Read how to check IPO allotment status or see all IPOs awaiting allotment.

Symbiotec Pharmalab IPO Lot Size & Minimum Investment

At upper price band of ₹988
ApplicationLotsSharesAmount
Retail (Min) 1 15 ₹14,820
Retail (Max) 13 195 ₹1,92,660
S-HNI (Min) 14 210 ₹2,07,480
S-HNI (Max) 67 1,005 ₹9,92,940
B-HNI (Min) 68 1,020 ₹10,07,760

Symbiotec Pharmalab IPO analysis: what the numbers say

Symbiotec Pharmalab is a pharmaceutical and biotechnology firm that develops and produces specialty goods, nutritional supplements, and active pharmaceutical compounds. The ₹1,757 Cr issue combines a fresh issue of ₹150 Cr, which goes to the company, and an offer for sale (OFS) of ₹1,607 Cr by existing shareholders, so about 9% of the money raised reaches the business.

Revenue rose from ₹572.97 Cr in FY23 to ₹755.98 Cr in FY25, a compound annual growth of 14.9%. Profit after tax grew from ₹23.49 Cr to ₹96.79 Cr. That is a net profit margin of 12.8% in FY25. Borrowings were 0.66 times net worth at the end of FY25.

The issue closed subscribed 71.26x overall (QIB 172.03x, NII 73.63x and retail 12.96x). Symbiotec Pharmalab listed at ₹988 on 1 Sep 2026, 0.0% against the issue price of ₹988. The last GMP before listing had pointed to about ₹1,173, so it opened 18.7 points below the grey market estimate. It closed the first day at ₹1,097.7 (+11.1%).

Worked out by IPO Darbaar from the offer document, exchange data and the latest GMP. For information only, not a recommendation.

Symbiotec Pharmalab IPO Issue Structure

Fresh issue ₹150 Cr (8.5%) Offer for sale ₹1,607 Cr (91.5%)
Face value₹2 / share
Market cap (post issue)—
Promoter holding (pre)34.47%
Promoter holding (post)—
Promoters
Anil Satwani, Kashish Satwani, Sushil Satwani, Satwani Holdings LLP
Book running lead managers
JM Financial Ltd.

Objects of the Symbiotec Pharmalab IPO

  1. Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company. ~ Rs. 112.50 Cr.
  2. General Corporate Purposes.

Symbiotec Pharmalab IPO Strengths & Risks

Strengths

  • Leading the world in steroidal-hormone and corticosteroid APIs
  • Long-standing connections with a domestic and international clientele
  • Fully funded, vertically integrated, multi-scale manufacturing platform with a spotless regulatory record and sustainable practices.
  • Constant R&D investment, with superior technological prowess compared to Indian counterparts.

Risks

  • Customers and regulatory bodies periodically check and audit the company's manufacturing facilities. Any manufacturing or quality control failure could lead to negative repercussions on business and financial performance, reputational harm, and regulatory action.
  • Customers outside of India account for a sizable amount of the company's revenue, accounting for 66.67%, 55.19%, 59.97%, and 52.76% of operating revenue in the three months ending June 30, 2025, and Fiscal 2025, 2024, and 2023, respectively.
  • A percentage of the company's raw material needs are sourced from nations like China and the US. Any unfavorable events in these nations or modifications to the import regulations could interfere with the raw material supply and negatively impact the business's operational outcomes.

Symbiotec Pharmalab Financials

Restated, ₹ crore
Revenue Profit after tax
Period ended FY2331 Mar 2023FY2431 Mar 2024FY2531 Mar 2025
Revenue 572.97723.33755.98
Profit after tax 23.49100.0696.79
Net worth 621.17720.68821.15
Total assets 989.991,294.791,579.65
Total borrowings 217.88247.21540.92
PAT margin 4.1%13.83%12.8%

Symbiotec Pharmalab Key Performance Indicators (KPIs)

ROE12.66%
ROCE11.8%
RoNW11.79%

About Symbiotec Pharmalab IPO

Symbiotec Pharmalab is a mainboard IPO worth ₹1,757 crore with a price band of ₹988 per share. The issue opens on 24 August 2026 and closes on 27 August 2026. Shares are expected to list on 1 September 2026 on BSE, NSE.

Symbiotec Pharmalab IPO is a Mainboard IPO with an issue size of Rs. 1,757 Cr by Symbiotec Pharmalab Limited, which is a pharmaceutical and biotechnology firm that develops and produces specialty goods, nutritional supplements, and active pharmaceutical compounds. The business serves both home and foreign markets in both developed and developing nations.

It places a strong emphasis on sustainable methods, quality compliance, and manufacturing that is driven by research.

Symbiotec Pharmalab Ltd. provides premium, cutting-edge chemicals that meet international standards to help the pharmaceutical, nutraceutical, and wellness sectors.

With more than 30 years of experience in the industry, they have developed from a lab-scale manufacturer of steroidal-hormone APIs in 1995 to an industrial-scale, backward-integrated platform with approvals from the US Food and Drug Administration ("US FDA"), European Union Good Manufacturing Practices ("EU-GMP"), Korea's Ministry of Food and Drug Safety, and other international organizations.

This new IPO is to be launched on 24 Aug 2026, and its ‘initial public offering’ will end on 27 Aug 2026

Symbiotec Pharmalab IPO: FAQs

What is the subscription status of Symbiotec Pharmalab IPO?

The issue closed subscribed 71.26x overall (QIB 172.03x, NII 73.63x and retail 12.96x). Figures are from NSE and cover bids on both exchanges.

What was the listing price of Symbiotec Pharmalab IPO?

Symbiotec Pharmalab listed at ₹988 on 1 Sep 2026, 0.0% against the issue price of ₹988. The last GMP before listing had pointed to about ₹1,173, so it opened 18.7 points below the grey market estimate. It closed the first day at ₹1,097.7 (+11.1%).

What is the price band of Symbiotec Pharmalab IPO?

The Symbiotec Pharmalab IPO price band is ₹988 per share and the issue size is ₹1,757 crore.

What is the lot size and minimum investment for Symbiotec Pharmalab IPO?

One lot of Symbiotec Pharmalab IPO has 15 shares. The minimum application for retail investors is 1 lot (15 shares), which costs ₹14,820 at the upper price band.

When does Symbiotec Pharmalab IPO open and close?

Symbiotec Pharmalab IPO opens for subscription on Monday, 24 August 2026 and closes on Thursday, 27 August 2026. Bids are accepted until 5 PM on the closing day.

What is the Symbiotec Pharmalab IPO allotment date?

The basis of allotment for Symbiotec Pharmalab IPO is expected to have been finalised on Friday, 28 August 2026, one working day after the issue closes (SEBI T+3 timeline).

How to check Symbiotec Pharmalab IPO allotment status?

Visit the website of the registrar, MUFG Intime (Link Intime), select Symbiotec Pharmalab IPO and search by PAN or application number. You can also check on the IPO allotment status page or on the BSE and NSE websites.

When is Symbiotec Pharmalab IPO listing date?

Symbiotec Pharmalab shares listed on BSE, NSE on Tuesday, 1 September 2026 at ₹988 per share.

Is Symbiotec Pharmalab a mainboard or SME IPO?

Symbiotec Pharmalab is a mainboard IPO, listing on the main board of BSE, NSE.

Last updated 28 Sep 2026, 11:55 PM IST. GMP is unofficial and indicative; dates after the issue closes are tentative. Not investment advice.